Biliary Tract Carcinoma Clinical Trial
Official title:
A Single-arm, Open, Single-center Phase II Clinical Study on the Efficacy and Safety of SBRT Sequential Surufatinib Combined With Immunotherapy for Locally Unresectable or Recurrent Biliary Tract Cancer After First Surgery
This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent biliary tract cancer after the first surgery.
This is a single-arm, open, single-center Phase II clinical study to observe and evaluate the efficacy and safety of SBRT sequential surufatinib combined with immunotherapy in patients with locally unresectable or recurrent biliary tract cancer after the first surgery.The study was divided into three stages: screening period, treatment period and follow-up period. During treatment, imaging methods were used to evaluate tumor status every 6 weeks (±7 days) until disease progression (PD, RECIST 1.1) or death (during treatment) or toxicity became intolerable, and tumor treatment and survival status after disease progression were recorded. Safety outcome measures included AE, changes in laboratory test values, vital signs and electrocardiogram changes. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT04003896 -
A Study to Evaluate Abemaciclib in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
| Active, not recruiting |
NCT04003636 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)
|
Phase 3 | |
| Not yet recruiting |
NCT05064852 -
A Real-world Study of the Safety and Efficacy of Surufatinib in the Treatment of Biliary Tract Carcinoma
|
||
| Recruiting |
NCT05668884 -
GEMOX Combined With Donafenib and Tislelizumab in Advanced Biliary Tract Carcinoma
|
Phase 2 | |
| Recruiting |
NCT05123482 -
A Phase I/IIa Study of AZD8205 Given Alone or in Combination With Anticancer Drugs, in Participants With Advanced or Metastatic Solid Malignancies
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT02151084 -
A Study of Different Dosing Schedules of Selumetinib With Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Biliary Cancer
|
Phase 2 | |
| Recruiting |
NCT06048133 -
Study of Gemcitabine, Cisplatin, AB680 and AB122 During First Line Treatment of Advanced Biliary Tract Cancers (QUIC)
|
Phase 2 | |
| Recruiting |
NCT05845554 -
Application of Chromosomal Instability in Early Diagnosis of Biliary Tract Carcinoma
|
||
| Completed |
NCT00490399 -
Trial of Gemcitabine and Cisplatin in Patients With Inoperable Biliary Tract Carcinomas
|
Phase 2 | |
| Completed |
NCT04067960 -
Pharmacogenomics Testing in Directing the Optimal Use of Supportive Care Medications in Patients With Stage III-IV Cancer
|
Early Phase 1 | |
| Not yet recruiting |
NCT06430827 -
Clinical Study of Irinotecan Hydrochloride Liposome Combined With Capecitabine for Second-line Treatment in Patients With Advanced or Metastatic Biliary Tract Carcinoma
|
Phase 2 | |
| Withdrawn |
NCT02105350 -
A Study of MEK162 With Gemcitabine and Oxaliplatin in Biliary Cancer
|
Phase 1 | |
| Recruiting |
NCT06047990 -
Endobiliary Percutaneous Cryobiopsy in Malignant Biliary Obstruction
|
N/A | |
| Active, not recruiting |
NCT04924062 -
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension Study
|
Phase 3 | |
| Not yet recruiting |
NCT06463548 -
Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract Carcinoma
|
N/A | |
| Terminated |
NCT04178460 -
A Study of Niraparib Combined With MGD013 in Patients With Advanced or Metastatic Solid Tumor Who Failed Prior Treatment
|
Phase 1 | |
| Completed |
NCT03027284 -
A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05023109 -
GP Chemotherapy in Combination With Anti-PD-1 and Anti-TIGIT in Unresectable Advanced BTC
|
Phase 2 | |
| Not yet recruiting |
NCT06168292 -
Intraductal Radiofrequency Thermoablation and Radiotherapy Combined Treatment for Extrahepatic Cholangiocarcinoma
|
N/A | |
| Recruiting |
NCT04979663 -
GEMOX Combined With Donafenib and Tislelizumab in Biliary Tract Cancer
|
Phase 1/Phase 2 |